Global Antibody Production Industry is Expecting Major Revenue Growth in Near Future

 A number of factors such as the improved approval rate for therapeutic antibodies by regulatory authorities, patent expiry of blockbuster monoclonal antibodies, increasing adoption of targeted immunotherapy, and increased R&D expenditure of pharmaceutical and biotechnology companies are key drivers for the growth of the antibody production market.

This report studies the antibody production market for the forecast period of 2016 to 2021. This market is expected to reach USD 13.28 Billion by 2021 from USD 7.45 Billion in 2016, at a CAGR of 12.3%.

Moreover, the increasing risk of infectious diseases and rising demand for protein therapeutics are expected to drive market growth during the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=181543091

On the basis of end user, the antibody production market is segmented into pharmaceutical and biotechnology companies, research institutes, and diagnostic laboratories. The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the market in 2016, and is projected to register the highest CAGR during the forecast period.

Target Audience:

# Equipment and consumable manufacturing companies
# Equipment and consumable suppliers and distributors
# Research institutes
# Venture capitalists
# Biotechnology and pharmaceutical companies
# Diagnostic laboratories

Geographically, the global antibody production market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). North America is expected to account for the largest share of the antibody production market in 2016, followed by Europe. The Asia-Pacific region offers significant growth opportunities for companies offering antibody production products, and is projected to grow at the highest CAGR during the forecast period.

Objectives of this Study:

# To define, describe, and forecast the global antibody production market on the basis of process, end user, and region.

# To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges).

# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.

# To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.

# To forecast the size of the market with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World.

# To strategically profile the key players in the global antibody production market and comprehensively analyze their core competencies.

# To track and analyze competitive developments such as joint ventures and alliances, mergers and acquisitions, new product/technology development, and research and development activities of the leading players in the global market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=181543091

Prominent players in the antibody production market include GE Healthcare (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Pall Corporation (U.S.), Sigma-Aldrich Corporation (Germany), Eppendorf AG (Germany), Cellab GmbH (Germany), INTEGRA Biosciences AG (Switzerland), and FiberCell Systems Inc. (U.S.).